NFKB1 and laryngeal carcinoma: It has been shown to function as a tumor suppressor by inhibiting the NF-κB pathway in various cancers, including breast cancer (Liu et al., 2015; Wu et al., 2018), melanoma (Bian et al., 2017), non-small cell lung cancer (Lu et al., 2017), nasopharyngeal carcinoma (Zhang et al., 2019), laryngeal cancer (Yang et al., 2018), and ESCC (Lu et al., 2018).